Why regulators can’t agree if aging is treatable, and what ICD-11’s “old age” code and the FDA’s stance mean for longevity drugs in 2026.
Is Aging a Disease? The FDA and ICD-11 Debate Explained Read More »
In a move that sent shockwaves through the longevity community, biohacker Bryan Johnson — the 47-year-old who has spent over $2 million annually in pursuit of biological immortality — has publicly abandoned rapamycin after concluding the drug may have accelerated his aging process. The reversal, announced in early 2025 and widely covered in international media,
Rapamycin — originally developed a an immuno uppre ant for organ tran plant patient — ha become one of the mo t debated and tudied compound in the long
In January 2026, something quietly historic happened at the U.S. Food and Drug Administration. For the first time ever, the agency cleared an epigenetic.
First Cellular Reprogramming Therapy and Age Reversal Read More »
What Is Rapamycin and Why Is It the Most Promising Longevity Drug of 2026? Rapamycin — also known as sirolimus — has emerged as the single most.
Rapamycin for Longevity in 2026: Science and Dosing Read More »
GLP-1 Receptor Agonists: The Most Exciting Longevity Drug Class of the Decade Semaglutide, tirzepatide, and their next-generation successors have.
The GLP-1 Revolution Beyond Weight Loss: A New Chapter in Longevity Medicine In 2026, glucagon-like peptide-1 (GLP-1) receptor agonists have transcended.
